We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Severity Biomarker Found for Leprosy and Leishmaniasis

By LabMedica International staff writers
Posted on 14 Apr 2017
Visceral leishmaniasis (VL) is a systemic, and most severe form of leishmaniasis and soluble CD163 (sCD163) levels can serve as biomarker for disease severity in several inflammatory disorder, including leprosy.

The CD163, receptor for the haptoglobin–hemoglobin complex, is expressed on monocytes/macrophages and neutrophils. More...
A soluble form of CD163 (sCD163) has been associated with the M2 macrophage phenotype, and M2 macrophages have been shown to down-modulate inflammatory responses.

Scientists at the Federal University of Sergipe enrolled leprosy patients and their pertinent controls at the Leprosy Clinic. They were classified according to the Madrid criteria of clinical forms: Indeterminate Leprosy (IL, n = 9), Tuberculoid Leprosy (TT, n = 14), Borderline Leprosy (BL, n = 14) and Lepromatous Leprosy (LL, n = 10. VL patients were divided into five groups; (1) before treatment (D0-Classic, n = 33), (2) 30 days after diagnosis with VL (after treatment) (D30, n = 19), (3) severe VL at day 0 (D0-SVL, n = 13), (4) asymptomatic (delayed type-hypersensitivity (DTH)-positive, n = 11) and (5) non-endemic health controls (HC, n = 8).

SCD163 quantification was performed at the same time for all sera samples by enzyme-linked immunosorbent assay (ELISA) kit. Haptoglobin was measured using a kit. Heme-oxygenase I and Arginase-1 were measured using commercial kits. Monocytes were isolated from peripheral blood and plated. Flow cytometry was performed on a FACS CANTO II.

The scientists reported sCD163 levels were significantly higher in patients with these diseases than those observed in healthy control individuals. Further analyses on infection and disease status of leprosy and VL patients revealed a clear association of sCD163 levels with clinical parameters of disease severity. In vitro culture assays revealed that Leishmania infection induced CD163 expression on the surface of both monocyte/macrophages and neutrophils, suggesting these cells as possible sources of sCD163. FACS analyses show that the cells expressing CD163 produces both Tumor necrosis factor alpha (TNF-α) and interleukin-4 (IL-4).

The authors concluded that their results reveal sCD163 as a potential biomarker of severity of diseases caused by intracellular pathogens Mycobacterium leprae and Leishmania spp. and have a modulatory role, with a mix of an inflammatory property induced by TNF-α release, but that potentially induces an anti-inflammatory T cell response, related to IL-4 release. The study was published on March 29, 2017, in the journal Public Library of Science Neglected Tropical Diseases.


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR Setup
ESTREAM
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The new RABTA sets a high standard in laboratory diagnostics (Photo courtesy of Randox)

Pioneering Analyzer with Advanced Biochip Technology Sets New Standard in Lab Diagnostics

A state-of-the-art analyzer combines advanced technology with exceptional efficiency to meet the demanding needs of modern laboratories. Randox Toxicology (Antrim, Ireland) has launched its pioneering... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.